Viridium and EFX Laboratories Enter Into Amalgamation Agreement

The Amalgamation

Pursuant to the Amalgamation Agreement, Viridium will acquire all of the issued and outstanding EFX Shares by the issuance of common shares in the capital of Viridium (the “Viridium Shares“), which will be issued on the basis of one Viridium Share for every 2.57 EFX Shares.

Upon completion of the Amalgamation, it is anticipated that the current holders of EFX Shares will hold approximately 48,172,257 Viridium Shares, representing approximately 49.41% of the outstanding Viridium Shares and the current holders of Viridium Shares will hold 49,320,375 Viridium Shares, representing approximately 50.59% of the outstanding Viridium Shares. No new control person will be created as a result of the Amalgamation.

The Amalgamation is expected to constitute an arm’s length “reviewable transaction” as that term is defined by the TSX Venture Exchange (the “Exchange“).

Significant Conditions to Closing

The completion of the Amalgamation is subject to the satisfaction of a number of conditions, including but not

... read more at: